ECSP21060962A - PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Google Patents

PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM

Info

Publication number
ECSP21060962A
ECSP21060962A ECSENADI202160962A ECDI202160962A ECSP21060962A EC SP21060962 A ECSP21060962 A EC SP21060962A EC SENADI202160962 A ECSENADI202160962 A EC SENADI202160962A EC DI202160962 A ECDI202160962 A EC DI202160962A EC SP21060962 A ECSP21060962 A EC SP21060962A
Authority
EC
Ecuador
Prior art keywords
meloxicam
migraine
rizatriptan
pain
administered
Prior art date
Application number
ECSENADI202160962A
Other languages
Spanish (es)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71947112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP21060962(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of ECSP21060962A publication Critical patent/ECSP21060962A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

Se describe en la presente composiciones que comprenden un NSAID como meloxicam y/o rizatriptan en combinación con una ciclodextrina y/o un carbonato o un bicarbonato. Estas composiciones pueden ser oralmente administradas, por ejemplo, para mejorar la biodisponibilidad o farmacocinéticas del NSAID para el tratamiento de dolor como migraña, artritis, y otras afecciones. También se describen aquí métodos para tratar el dolor, como migraña, que comprenden administrar meloxicam y rizatriptan a un ser humano que sufre de dolor, como migraña. Para la migraña, estos métodos pueden ser particularmente útiles cuando el meloxicam y el rizatriptan son administrados mientras el ser humano está sufriendo de un ataque agudo de dolor de migraña o aura de migraña. En algunas modalidades, la combinación de meloxicam y rizatriptan pueden ser administrados en una forma que resulta en una Tmax de meloxicam de 3 horas o menos.Described herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions can be administered orally, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human suffering from pain, such as migraine. For migraine, these methods may be particularly useful when meloxicam and rizatriptan are administered while the human is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan can be administered in a manner that results in a meloxicam Tmax of 3 hours or less.

ECSENADI202160962A 2019-02-06 2021-08-17 PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM ECSP21060962A (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962802198P 2019-02-06 2019-02-06
US201962803756P 2019-02-11 2019-02-11
US201962835613P 2019-04-18 2019-04-18
US201962846311P 2019-05-10 2019-05-10
US201962860705P 2019-06-12 2019-06-12
US201962895933P 2019-09-04 2019-09-04
US201962895956P 2019-09-04 2019-09-04
US201962955905P 2019-12-31 2019-12-31

Publications (1)

Publication Number Publication Date
ECSP21060962A true ECSP21060962A (en) 2021-11-30

Family

ID=71947112

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202160962A ECSP21060962A (en) 2019-02-06 2021-08-17 PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM

Country Status (19)

Country Link
EP (1) EP3920909A4 (en)
JP (5) JP7237386B2 (en)
KR (2) KR20210118880A (en)
CN (1) CN113423397A (en)
AU (3) AU2020218253B2 (en)
BR (1) BR112021015467A2 (en)
CA (2) CA3213549A1 (en)
CL (1) CL2021002070A1 (en)
CO (1) CO2021010380A2 (en)
CR (1) CR20210420A (en)
EC (1) ECSP21060962A (en)
IL (1) IL285389A (en)
MA (1) MA54904A (en)
MX (2) MX2021009435A (en)
MY (1) MY198967A (en)
NZ (1) NZ778435A (en)
PE (1) PE20212157A1 (en)
SG (1) SG11202107926XA (en)
WO (1) WO2020163620A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230125826A (en) * 2020-12-31 2023-08-29 액섬 테라퓨틱스, 인크. Pharmaceutical composition comprising meloxicam
KR20260074736A (en) * 2023-09-18 2026-05-26 액섬 테라퓨틱스, 인크. Pharmaceutical composition containing meloxicam

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2234324T3 (en) * 1998-11-02 2005-06-16 MERCK & CO., INC. COMBINATIONS OF A 5HT1B / 1D AGONIST AND A COX-2 SELECTIVE INHIBITOR FOR THE TREATMENT OF MIGRAINE.
US20040214861A1 (en) * 2003-03-28 2004-10-28 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
WO2004089365A1 (en) 2003-04-11 2004-10-21 Pfizer Limited Pharmaceutical combination comprising eletriptan and sodium bicarbonate
BRPI0410807A (en) 2003-06-06 2006-06-27 Glaxo Group Ltd pharmaceutical composition and method for treating a mammal suffering from or susceptible to conditions associated with headache
EP3216445A1 (en) 2004-05-28 2017-09-13 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20090068262A1 (en) * 2007-04-04 2009-03-12 Ilan Zalit Rapid dissolution of combination products
PL3100728T3 (en) * 2009-05-13 2020-05-18 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
SG10202010157VA (en) * 2015-02-10 2020-11-27 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam
US10058614B2 (en) 2015-02-10 2018-08-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
SMT202600087T1 (en) * 2016-09-23 2026-03-09 Teva Pharmaceuticals Int Gmbh Treating refractory migraine
US10471014B2 (en) * 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
DK3565550T3 (en) * 2017-01-04 2021-01-18 Axsome Therapeutics Inc PHARMACEUTICAL COMPOSITIONS INCLUDING MELOXICAM AND RIZATRIPTANE
KR102583443B1 (en) * 2017-05-10 2023-09-26 액섬 테라퓨틱스, 인크. Pharmaceutical compositions comprising meloxicam

Also Published As

Publication number Publication date
JP2022519670A (en) 2022-03-24
JP2023062144A (en) 2023-05-02
MA54904A (en) 2021-12-15
BR112021015467A2 (en) 2021-10-05
JP7420990B2 (en) 2024-01-23
JP7237386B2 (en) 2023-03-13
EP3920909A1 (en) 2021-12-15
CR20210420A (en) 2021-12-22
MX2021009435A (en) 2021-09-10
AU2020218253A1 (en) 2021-08-12
JP7862619B2 (en) 2026-05-19
JP2026116506A (en) 2026-07-09
JP2024026732A (en) 2024-02-28
CA3128940C (en) 2023-11-07
CN113423397A (en) 2021-09-21
PE20212157A1 (en) 2021-11-09
NZ778435A (en) 2024-12-20
CA3213549A1 (en) 2020-08-13
SG11202107926XA (en) 2021-08-30
KR20210118880A (en) 2021-10-01
IL285389A (en) 2021-09-30
AU2023202545A1 (en) 2023-05-18
MY198967A (en) 2023-10-05
MX2026005800A (en) 2026-06-01
KR20260066814A (en) 2026-05-12
WO2020163620A1 (en) 2020-08-13
CA3128940A1 (en) 2020-08-13
AU2020218253B2 (en) 2023-02-23
AU2025230695A1 (en) 2025-10-02
CO2021010380A2 (en) 2021-09-30
JP7620125B2 (en) 2025-01-22
EP3920909A4 (en) 2022-11-30
CL2021002070A1 (en) 2022-04-01
JP2025061137A (en) 2025-04-10
AU2023202545B2 (en) 2025-06-12

Similar Documents

Publication Publication Date Title
MX2021014509A (en) PHARMACEUTICAL COMPOSITIONS INCLUDING MELOXICAM.
MX2024005716A (en) Pharmaceutical compositions comprising meloxicam.
MX2022000143A (en) NOVELTY METHODS.
JOP20210050A1 (en) Modulators of pnpla3 expression
JP2017149726A5 (en)
CO2020004034A2 (en) Methods for the treatment of muscular dystrophy
ECSP19014247A (en) DOSAGE FORMS TO TREAT AND PREVENT SLEEP DISORDERS
CL2021002070A1 (en) Pharmaceutical compositions comprising meloxicam.
EA200701195A1 (en) CONTAINING CEFALOSPORIN COMPOSITIONS WITH NANOPARTICLES AND WITH CONTROLLED DELIVERY
CO6531463A2 (en) COMBINATIONS OF A PI3K INHIBITOR AND A MEK INHIBITOR
CL2018001420A1 (en) Treatment of cognitive disorders with (r) -7-chloro-n- (quinuclidin-3-yl) benzo [b] thiophene-2-carboxamide and pharmaceutically acceptable salts thereof. (divisional application 201701853)
CL2018000811A1 (en) Modified-release amino acid formulations administered orally.
EA201692392A1 (en) NEW MEDICINE FORM OF MELOXYCAM
MX2020010417A (en) RET INHIBITOR FOR USE IN TREATING CANCER HAVING A RET ALTERATION.
JOP20200291A1 (en) Expression rates of APOL1
CL2008003201A1 (en) Pharmaceutical composition comprising 0.5 to 50 mg of gaboxadol or a pharmaceutically acceptable salt thereof, and one or more inhibitors of pat1 and / or one or more inhibitors of oat, wherein said composition provides an in vivo plasma profile with a tmax longer than 20 minutes, useful in sleep disorders treatments.
PH12019500349A1 (en) Diacylglycerol acyltransferase 2 inhibitors
BR112019009726A2 (en) combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease
CO2021007006A2 (en) Modulators of irf5 expression
BR122021012549B8 (en) ORAL MELATONIN DISSOLUTION COMPOSITION WITH ACIDIFYING AGENT THAT MAKES MELATONIN SOLUBLE IN SALIVA
AR114306A1 (en) TREATMENT AND PREVENTION OF SLEEP DISORDERS
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
MX2020003660A (en) Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections.
CO2021001528A2 (en) Synergistic pharmaceutical combination of a selective cyclooxygenase 2 inhibitor and an anthraquinone derivative
MX2018015208A (en) ANDROGRAPHOLID TO TREAT PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS.